deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT04051944

A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Sponsor: UCB Biopharma SRL

Conditions Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions Rozanolixizumab
Updated 21 times since 2019 Last updated: Oct 6, 2022 Started: Aug 21, 2019 Primary completion: Nov 10, 2021 Completion: Nov 10, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and is currently completed. UCB Biopharma SRL leads this study, which shows 21 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~May 2022 · 5 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. May 2022 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 16 earlier versions

  1. Dec 2021 — May 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Oct 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Enrolling By Invitation → Active Not Recruiting

  4. May 2021 — Sep 2021 [monthly]

    Enrolling By Invitation PHASE2

  5. Apr 2021 — May 2021 [monthly]

    Enrolling By Invitation PHASE2

  6. Mar 2021 — Apr 2021 [monthly]

    Enrolling By Invitation PHASE2

  7. Feb 2021 — Mar 2021 [monthly]

    Enrolling By Invitation PHASE2

  8. Jan 2021 — Feb 2021 [monthly]

    Enrolling By Invitation PHASE2

  9. Jul 2020 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE2

  10. Jun 2020 — Jul 2020 [monthly]

    Enrolling By Invitation PHASE2

  11. May 2020 — Jun 2020 [monthly]

    Enrolling By Invitation PHASE2

  12. Apr 2020 — May 2020 [monthly]

    Enrolling By Invitation PHASE2

  13. Feb 2020 — Apr 2020 [monthly]

    Enrolling By Invitation PHASE2

  14. Nov 2019 — Feb 2020 [monthly]

    Enrolling By Invitation PHASE2

  15. Oct 2019 — Nov 2019 [monthly]

    Enrolling By Invitation PHASE2

    Status: Not Yet Recruiting → Enrolling By Invitation

  16. Sep 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Aug 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UCB Biopharma SRL
Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Augusta, United States , Barcelona, Spain , Charlotte, United States , Copenhagen, Denmark , Durham, United States , Essen, Germany , Ghent, Belgium , Göttingen, Germany , Leuven, Belgium and 4 more locations